Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

NeoGenomics introduces new molecular assay that detects SF3B1 gene mutations

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today that it has validated and launched the first molecular assay for clinical use in the United States that detects mutations in the SF3B1 gene (splicing factor 3b, subunit 1).

6 Aug 2012

Novartis, Penn partner to study and commercialize novel cellular immunotherapies for cancer

In an alliance aimed at bringing a new, personalized immunotherapy approach to patients with a wide variety of cancers, the University of Pennsylvania and Novartis announced today an exclusive global research and licensing agreement to further study and commercialize novel cellular immunotherapies using chimeric antigen receptor (CAR) technologies.

6 Aug 2012

Researchers identify how telomerase is recruited to chromosome ends

Stem cells are special. Nestled in muscle and skin, organ and bone, they bide their time over years or decades until called to replace damaged or lost tissue. One secret to their longevity is an enzyme called telomerase, which stills the relentless ticking of the molecular clock that limits the life span of other cells.

3 Aug 2012

NYGC purchases four Life Technologies' Ion Proton Sequencers

Life Technologies Corporation today announced that the New York Genome Center (NYGC) has purchased four Ion Proton Sequencers for its new Innovation Center.

31 Jul 2012

Population Genetics validates GenomePooling™ for cancer

Population Genetics Technologies Ltd., creator of innovative methods for genetic analyses and biomarker discovery, has successfully completed a pilot study to prove that its GenomePooling™ method is sensitive and accurate enough to detect even small percentages of gene variants within cancer tissue. This validates the method’s suitability for use in IntReALL 2010, the world’s largest genetic analysis of acute lymphoblastic leukaemia (ALL) relapse cases. ALL is the most common childhood malignant disease.

31 Jul 2012

GenomePooling™ method is sensitive and accurate

31 Jul 2012

TAU researcher reveals link between plant and human biology

Increasingly, scientists are uncovering surprising biological connections between humans and other forms of life. Now a Tel Aviv University researcher has revealed that plant and human biology is much closer than has ever been understood - and the study of these similarities could uncover the biological basis of diseases like cancer as well as other "animal" behaviors.

31 Jul 2012

Traditional cures provide economic benefits

For millions of people around the world being sick doesn't mean making a trip to the local pharmacy for medicines like Advil and Nyquil. Instead it means turning to the forest to provide a pharmacopeia of medicines to treat everything from tooth aches to chest pains.

31 Jul 2012

Viewpoints: Health law no threat to innovation; Failure to expand Medicaid would 'doom' thousands; Don't stigmatize mentally ill

For better or worse, the Democrats incorporated a good deal of mainstream Republican thinking about health care reform from the past decade, including mandated coverage and health insurance exchanges, into the Affordable Care Act. This leaves the GOP, embarrassingly, with little to say about what is wrong with the act.

31 Jul 2012

New assay method finds evidence of clonal evolution in chronic lymphocytic leukemia

Using a new assay method to study tumor cells, researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center have found evidence of clonal evolution in chronic lymphocytic leukemia (CLL).

30 Jul 2012

ARIAD Pharmaceuticals commences ponatinib Phase 3 trial in newly diagnosed CML

ARIAD Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 3 trial of ponatinib, its investigational pan-BCR-ABL inhibitor, in adult patients with newly diagnosed chronic myeloid leukemia (CML).

28 Jul 2012

PedBrain Tumor network publishes evaluation of first 125 genome analyses of medulloblastomas

Brain tumors are the primary cause of cancer mortality in children. Even if a cure is possible, young patients often suffer from the stressful treatment which can be harmful to the developing brain. The most common childhood brain tumors are medulloblastoma and pylocytic astrocytoma.

27 Jul 2012

University of York researchers launch major study of lymphoma and myeloma

Researchers at the University of York are launching a major study of lymphoma and myeloma aimed at promoting earlier diagnosis and improving survival for patients with these cancers, which are among the most common in the UK.

27 Jul 2012

Coca-Cola sold in California now contains little of cancer-causing chemical 4-methylimidizole

Carcinogenicity and regulation of caramel colorings by Michael Jacobson, (Executive Director, Center for Science in the Public Interest, USA), an article due to be published in the International Journal of Occupational and Environmental Health, states that Coca-Cola sold in California now contains little of the cancer-causing chemical 4-methylimidizole (4-MI).

27 Jul 2012

Fusion of FGFR and TACC gene leads to glioblastoma

Researchers at Columbia University Medical Center (CUMC) have discovered that some cases of glioblastoma, the most common and aggressive form of primary brain cancer, are caused by the fusion of two adjacent genes.

26 Jul 2012

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

Gilead Sciences, Inc. announced today its results of operations for the quarter ended June 30, 2012.

26 Jul 2012

American Society of Hematology announces new grant program for biomedical research

The American Society of Hematology (ASH), the world's largest professional organization dedicated to the causes and treatment of blood disorders, today announced its commitment of $9 million over a three-year period to provide funding, in the form of bridge grants, for its hematologists whose vital research will not be accomplished due to the severe funding reductions for biomedical research.

26 Jul 2012

Researchers decipher function of β-catenin in generating blood tissue stem cells

Researchers from IMIM (Hospital del Mar Medical Research Institute) have deciphered the function executed by a protein called β-catenin in generating blood tissue stem cells.

26 Jul 2012

Bio-Path initiates enrollment in fourth cohort of Liposomal Grb-2 Phase I trial for blood cancers

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has begun enrolling patients into the fourth dosage cohort in its Phase I clinical trial of its lead product candidate, BP-100.1.01 (Liposomal Grb-2), which is being evaluated as a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS).

26 Jul 2012

CytRx commences aldoxorubicin plus doxorubicin Phase 1b trial in advanced solid tumors

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 1b clinical trial to determine the maximum tolerated dose and to evaluate preliminary efficacy of aldoxorubicin (formerly INNO-206) administered in combination with the commonly used chemotherapeutic agent doxorubicin in patients with advanced solid tumors who have failed other therapies.

26 Jul 2012

Leukemia News and Research

Further Reading

NeoGenomics introduces new molecular assay that detects SF3B1 gene mutations

Novartis, Penn partner to study and commercialize novel cellular immunotherapies for cancer

Researchers identify how telomerase is recruited to chromosome ends

NYGC purchases four Life Technologies' Ion Proton Sequencers

Population Genetics validates GenomePooling™ for cancer

GenomePooling™ method is sensitive and accurate

TAU researcher reveals link between plant and human biology

Traditional cures provide economic benefits

Viewpoints: Health law no threat to innovation; Failure to expand Medicaid would 'doom' thousands; Don't stigmatize mentally ill

New assay method finds evidence of clonal evolution in chronic lymphocytic leukemia

ARIAD Pharmaceuticals commences ponatinib Phase 3 trial in newly diagnosed CML

PedBrain Tumor network publishes evaluation of first 125 genome analyses of medulloblastomas

University of York researchers launch major study of lymphoma and myeloma

Coca-Cola sold in California now contains little of cancer-causing chemical 4-methylimidizole

Fusion of FGFR and TACC gene leads to glioblastoma

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

American Society of Hematology announces new grant program for biomedical research

Researchers decipher function of β-catenin in generating blood tissue stem cells

Bio-Path initiates enrollment in fourth cohort of Liposomal Grb-2 Phase I trial for blood cancers

CytRx commences aldoxorubicin plus doxorubicin Phase 1b trial in advanced solid tumors

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News